Log in

Relevant bibliographies by topics / PN 35.5 UL 2008

Contents

Journal articles

Academic literature on the topic 'PN 35.5 UL 2008'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PN 35.5 UL 2008.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PN 35.5 UL 2008"

1

Seetharam, Mahesh, Olga K. Weinberg, Li Ren, et al. "AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome." Blood 114, no. 22 (2009): 2638. http://dx.doi.org/10.1182/blood.v114.22.2638.2638.

Full text

Abstract:

Abstract Abstract 2638 Poster Board II-614 Background: The importance of cytogenetics in prognosis of AML is now widely recognized and accepted in clinical practice. A recent study found that autosomal chromosomal monosomy predicted for an adverse outcome. The goal of this study is to characterize patients with monosomal karyotype by mutation status and clinical features. Methods: One-hundred forty consecutive AML patients diagnosed at Stanford University Hospital between 2005 and 2008 with adequate material for mutation analysis were studied. Cases were classified using the 2008 WHO criteria.

APA, Harvard, Vancouver, ISO, and other styles

2

Richardson, Paul G., Jordi Bruna, Anthony A. Amato, et al. "Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model." Blood 114, no. 22 (2009): 3860. http://dx.doi.org/10.1182/blood.v114.22.3860.3860.

Full text

Abstract:

Abstract Abstract 3860 Poster Board III-796 Bortezomib (Velcade®) therapy for multiple myeloma (MM) results in high overall and complete response rates, but can also lead to peripheral neuropathy (PN). Bortezomib-associated PN has been shown to be a cumulative, dose-related, primarily sensory neuropathy that is reversible to baseline in the majority of cases (Richardson et al, Br J Haematol 2009). Further research is needed to determine the mechanisms by which PN arises and to determine potential neuroprotective strategies. A preclinical model that reflects the neurophysiologic changes seen in

APA, Harvard, Vancouver, ISO, and other styles

3

Vera, L., R. Reategui, B. Beltran, et al. "The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru." Journal of Clinical Oncology 27, no. 15_suppl (2009): e19561-e19561. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19561.

Full text

Abstract:

e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined. Thus, this study is aimed to describe these features in cases from a Peruvian population. Methods: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008. We reviewed 2502 clinical records. The statistical method was descriptive and survival was calculated using the Kaplan-Meier method. Results: Forty-eight patients with HIV-associated lymphoma were identified. Male:female ratio w

APA, Harvard, Vancouver, ISO, and other styles

4

Bartsch, Fabian, Lisa-Katharina Heuft, Janine Baumgart, et al. "Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma." Journal of Clinical Medicine 10, no. 11 (2021): 2426. http://dx.doi.org/10.3390/jcm10112426.

Full text

Abstract:

(1) Background: Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy. Besides tumor, nodal, and metastatic status, the UICC TNM classification describes further parameters such as lymphangio- (L0/L1), vascular (V0/V1/V2), and perineural invasion (Pn0/Pn1). The aim of this study was to analyze the influence of these parameters on recurrence and survival. (2) Methods: All surgical explorations for patients with ICC between January 2008 and June 2018 were collected and further analyzed in our institutional database. Statistical analyses focused on perineural, lymphangio-, and vascular invas

APA, Harvard, Vancouver, ISO, and other styles

5

Cai, Yuli, Chao Liu, Ye Guo, et al. "Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China." Blood 134, Supplement_1 (2019): 5911. http://dx.doi.org/10.1182/blood-2019-125565.

Full text

Abstract:

Objective: Chronic myeloid leukemia (CML) is a rare disease among children. It comprises 3% of childhood leukemias. CML in children is different from CML in adult. Here we analyzed the clinical features and prognosis of pediatric CML in a single institute from China. Methods: A retrospective study was performed by reviewing clinical records of pediatric CML from 2002 to 2019. Results: A total of 48 pediatric CML cases were included in the study, with 35 males and 13 females (M: F=2.7:1). Four cases were diagnosed during 2002~2007, 12 cases during 2008~2013 and 32 cases during 2014~2019. Two (4

APA, Harvard, Vancouver, ISO, and other styles

6

Beltran, Brady E., Erick Cotacallapa, and Jorge J. Castillo. "Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma." Blood 120, no. 21 (2012): 1588. http://dx.doi.org/10.1182/blood.v120.21.1588.1588.

Full text

Abstract:

Abstract Abstract 1588 Background: EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a provisional entity included in the 2008 WHO Classification of Lymphomas. Diagnostic criteria include age >50 years, DLBCL morphology and EBV expression in lymphomatous cells. However, these criteria are evolving as several patients are <50 years and a specific cut-off for the percentage of EBV expression has not been defined. The goal of this retrospective study is to evaluate clinical and pathological characteristics of EBV+ DLBCL from Peruvian patients. Methods: Between Januar

APA, Harvard, Vancouver, ISO, and other styles

7

Chalasani, Venu, Wassim Kassouf, Joseph L. Chin, et al. "Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience." Canadian Urological Association Journal 5, no. 2 (2013): 83. http://dx.doi.org/10.5489/cuaj.587.

Full text

Abstract:

Background: Radical cystectomy may provide optimal survivaloutcomes in the management of clinical T1 bladder cancer. Wepresent our data from a large, multi-institutional, contemporaryCanadian series of patients who underwent radical cystectomy forclinical T1 bladder cancer in a single-payer health care system.Methods: We collected a pooled database of 2287 patients whounderwent radical cystectomy between 1993 and 2008 in 8 differentcentres across Canada; 306 of these patients had clinical T1bladder cancer. Survival data were analyzed using Kaplan-Meiermethod and Cox regression analysis.Results

APA, Harvard, Vancouver, ISO, and other styles

8

Rosenthal, Allison C., Amylou Constance Dueck, Katherine Gano, et al. "A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma." Blood 124, no. 21 (2014): 4410. http://dx.doi.org/10.1182/blood.v124.21.4410.4410.

Full text

Abstract:

Abstract Introduction Non-Hodgkin lymphoma responds to single agents such as cyclophosphamide, combination therapy such as CVP and immunotherapy with monoclonal antibodies such as rituximab. There is no consensus on the optimal treatment for relapsed low grade or mantle cell lymphoma. Based on the success and tolerability of combining alkylating agents with proteasome inhibitors in multiple myeloma, a phase II clinical trial of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBor-D) was designed to explore the efficacy and safety of this combination in relapsed low grade and man

APA, Harvard, Vancouver, ISO, and other styles

9

Beltran, Brady E., Julio C. Chavez, Eduardo M. Sotomayor, and Jorge J. Castillo. "Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse Large B-Cell Lymphoma." Blood 124, no. 21 (2014): 5408. http://dx.doi.org/10.1182/blood.v124.21.5408.5408.

Full text

Abstract:

Abstract Background: EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a provisional entity included in the 2008 WHO Classification of Lymphomas. Diagnostic criteria include age >50 years, DLBCL morphology and EBV expression in lymphomatous cells. However, these criteria are evolving as several patients younger than 50 years of age without immunodeficiency have been diagnosed. Also, a specific cut-off for the percentage of EBV expression has not been defined. Lymphopenia, monocytosis, neutrophil-to-lymphocyte ratio (NLR) and the lymphocyte-to-monocyte ratio (LMR) hav

APA, Harvard, Vancouver, ISO, and other styles

10

Yasenchak, Christopher A., Rodolfo Eduardo Bordoni, Dipti Patel-Donnelly, et al. "Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients." Journal of Clinical Oncology 38, no. 15_suppl (2020): 8032. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8032.

Full text

Abstract:

8032 Background: Older patients with classical Hodgkin lymphoma (cHL) have poor outcomes relative to younger patients, often due to comorbidities and toxicities related to standard first-line (1L) chemotherapy (5-yr PFS: 30%–45% vs 75%–80%) (Evens 2008; Proctor 2009). Brentuximab vedotin (BV, ADCETRIS®), a CD30-directed antibody-drug conjugate, has robust activity in patients refractory to several lines of chemotherapy. Methods: This phase 2, open-label study, SGN35-015 (NCT01716806), evaluated efficacy and tolerability of BV alone or combined with single-agents in treatment-naive cHL patients

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!